Vivos Therapeutics (NASDAQ:VVOS) Posts Earnings Results, Beats Estimates By $0.23 EPS

Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.23, Zacks reports. Vivos Therapeutics had a negative net margin of 122.00% and a negative return on equity of 2,325.64%.

Vivos Therapeutics Trading Down 16.1%

Vivos Therapeutics stock traded down $0.02 during trading on Monday, hitting $0.08. 4,970,300 shares of the company were exchanged, compared to its average volume of 4,962,193. The business’s 50 day moving average is $0.14 and its 200 day moving average is $0.66. Vivos Therapeutics has a 52 week low of $0.07 and a 52 week high of $2.69. The company has a market capitalization of $1.65 million, a P/E ratio of -0.04 and a beta of 6.37.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Vivos Therapeutics in a report on Thursday, October 15th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $2.80.

View Our Latest Stock Report on Vivos Therapeutics

About Vivos Therapeutics

(Get Free Report)

Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing oral appliances and related treatments for sleep-disordered breathing, including obstructive sleep apnea (OSA) and snoring. Its approach is designed to help improve upper-airway function through non-surgical, dentist-supervised therapies. The company’s primary products are its Vivos Complete Airway Repositioning and Expansion (CARE) oral appliances, which are customized for individual patients and intended for use during sleep.

Read More

Earnings History for Vivos Therapeutics (NASDAQ:VVOS)

Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.